Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRCA1 mutation
i
Other names:
BRCA1, BRCC1, PPP1R53, RNF53, Breast cancer 1, early onset
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
672
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
BSI 201
Sensitive: C3 – Early Trials
Oncologist - 3 days (New C3)
BSI 201
Sensitive
:
C3
Oncologist - 3d
BSI 201
Sensitive: C3 – Early Trials
Oncologist - 3 days
BSI 201
Sensitive
:
C3
Oncologist - 3 days - (New C3)
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
Anticancer Res - 1 week (New C3)
olaparib
Sensitive
:
A1
Anticancer Res - 1wk
olaparib
Sensitive: A1 - Approval
Anticancer Res - 1 week
olaparib
Sensitive
:
A1
Anticancer Res - 1 week - (New C3)
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks (New B)
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3wk
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3 weeks - (New B)
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
carboplatin + pegylated liposomal doxorubicin
Sensitive: C3 – Early Trials
Int J Gynecol Cancer - 3 weeks (New C3)
carboplatin + pegylated liposomal doxorubicin
Sensitive
:
C3
Int J Gynecol Cancer - 3wk
carboplatin + pegylated liposomal doxorubicin
Sensitive: C3 – Early Trials
Int J Gynecol Cancer - 3 weeks
carboplatin + pegylated liposomal doxorubicin
Sensitive
:
C3
Int J Gynecol Cancer - 3 weeks - (New C3)
BRCA1 mutation
Pancreatic Cancer
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA1 mutation
HER2 Negative Breast Cancer
BRCA1 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
BRCA1 mutation
HER2 Negative Breast Cancer
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
BRCA1 mutation
Pancreatic Adenocarcinoma
BRCA1 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
bevacizumab
Resistant: A2 - Guideline
bevacizumab
Resistant
:
A2
bevacizumab
Resistant: A2 - Guideline
bevacizumab
Resistant
:
A2
BRCA1 mutation
HER2 Negative Breast Cancer
BRCA1 mutation
HER2 Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
BRCA1 mutation
Breast Cancer
BRCA1 mutation
Breast Cancer
talazoparib
Sensitive: A2 - Guideline
talazoparib
Sensitive
:
A2
talazoparib
Sensitive: A2 - Guideline
talazoparib
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
pegylated liposomal doxorubicin
Sensitive
:
A2
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
pegylated liposomal doxorubicin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
BRCA1 mutation
Breast Cancer
BRCA1 mutation
Breast Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
talazoparib
Sensitive: A2 - Guideline
talazoparib
Sensitive
:
A2
talazoparib
Sensitive: A2 - Guideline
talazoparib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login